Our Science

Publications and Presentations

September 2024

SCY-247, A SECOND-GENERATION TRITERPENOID ANTIFUNGAL DEMONSTRATES BROAD TISSUE DISTRIBUTION AND EFFICACY IN MURINE FUNGAL INFECTION MODELS MSGERC, September 2024

April 2024

SCY-247, a Novel Second-Generation IV/Oral Triterpenoid Antifungal, Demonstrates In vitro Activity Against Fungal Pathogens, Including Azole-Resistant Strains of Candida and Aspergillus ECCMID, April 2024

April 2024

The novel second-generation IV/oral triterpenoid SCY-247 is efficacious in an experimental murine model of invasive candidiasis caused by Candida glabrata ECCMID, April 2024

January 2024

SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis AAAM, January 2024

October 2023

SCY-247, A SECOND-GENERATION IV/ORAL TRITERPENOID ANTIFUNGAL: IN VITRO ACTIVITY AGAINST A BROADSPECTRUM OF FUNGAL PATHOGENS, AND DOSE-DEPENDENT TISSUE DISTRIBUTION IN VIVO TIMM, October 2023

April 2023

Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open Label Studies: Difficult to Treat Invasive Fungal Infections (FURI) and Infections with Candida auris (CARES) ECCMID, April 2023

April 2023

FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Treated with Oral Ibrexafungerp ECCMID, April 2023

April 2023

A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step Down Therapy following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall Therapy ECCMID, April 2023

October 2022

All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI) IDWeek

September 2022

Outcomes of Oral Ibrexafungerp in Refractory Patients with Candida from an Interim Analysis of a Phase 3 Open-Label Study (FURI) MSGERC

< Prev Next >